App-Quantinova.ai

Hyperferritinaemia and EBV viraemia are poor predictors of HLH post allogeneic stem cell transplantation

S. Chia - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fibrinogen (IV)

The work load and efficiency of communication of Critical Results to GP out of hours service in Blood Sciences at Hull and East Yorkshire NHS Trust

N. Svenson - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Acute renal failure

N/A

Iatrogenic Iron Overload: Revisiting the practice of Iron Supplementation in the Era of Access to Iron Overload Monitoring Technology

L.D. Rahmartani - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Anemia

Deferasirox

Haematological investigations performed following incidental finding of diffusely abnormal bone marrow signal on Magnetic Resonance Imaging ‐ Results from a single UK Centre

P. Kalkur - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

N/A

Single Centre Immune Thrombocytopaenia Cohort Demographic Review

P. Woolley - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Challenges of Transitioning to an Ambulatory Care Model within Cardiff and Vale University Health Board (UHB)

B. Ingram - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Successful treatment of chronic neutrophilic leukaemia and associated giant cell arteritis with the combination of ruxolitinib and azacytidine

N. Herlihy - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myeloid neoplasms

Mycophenolate mofetil

A Retrospective analysis of electronic Haematology Advice & Guidance via NHS e‐Referral Service at University Hospitals of Leicester NHS Trust

S. Munireddy - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Investigating the underlying causes of iron deficiency anaemia and its management in a primary care setting in Birmingham

A. Devi - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

Glycopyranosyl lipid A

Severe Hepatotoxicity Following Tyrosine Kinase Inhibitor Use for the Treatment of Chronic Myeloid Leukaemia in Pregnancy

M. Narayanan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Chronic Myelogenous Leukemia

Flopen

Audit of reason, appropriateness and outcome of blood film referrals from the biomedical scientists to haematopathologists

A. Mohan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Single Centre Experience in the Use of Erythropoietin in Myelofibrosis Associated Anaemia and The Effect on Transfusion Requirements

S. Harvey - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Erythropoietin

Non Haematological Malignancies found as the principal diagnosis in New Patients referred to the Haematology Clinic

A. Fyfe - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Endometrial Cancer

N/A

Analysis into the Usage of Four Factor Human Prothrombin Complex

A. Mandal - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Prothrombin complex

A retrospective analysis of newly diagnosed primary severe immune thrombocytopenia treatment: a UK single‐centre study

M. Timmins - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Mycophenolate mofetil

The diagnosis of Polycythaemia Vera in JAK2V617F and JAK2 exon 12 negative patients‐ A Local Experience

C. Symonds - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Polycythaemia vera

Erythropoietin

Are real world response rates after TPO switch consistent with the literature? Single centre retrospective review

R. Dunk - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Eltrombopag

Efficacy and Safety of Single‐Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single‐Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3‐Internal Tandem Duplication (FLT3‐ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM‐R Trial

J.E. Cortes - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Mitoxantrone

Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non‐Hodgkin Lymphoma

J. Gribben - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Mucosa-associated lymphoid tissue lymphoma

Rituximab

Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)

A. McMillan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Polatuzumab vedotin

Filters

45280 Abstracts